Press Release
 |
| Press Release
ATHN Announces WAPPS-Hemo and ATHN Systems Integration Now Available — ROCHESTER, NY – April 21, 2021 – The American Thrombosis and Hemostasis Network (ATHN) is pleased to announce that the integration of WAPPS-Hemo—the Web-Accessible Population Pharmacokinetics Service for Hemophilia—and ATHN Systems is now available. Providers can now submit pharmacokinetic (PK) requests to WAPPS-Hemo directly through the ATHN Systems interface. This new service benefits patients, providers, and researchers, and is an exciting step in ATHN’s ongoing efforts to secure data, advance knowledge, and transform care. WAPPS-Hemo is a centralized, dedicated, actively moderated database that allows participating hemophilia treatment centers (HTCs) to input factor VIII and factor IX plasma levels from sparse samples and receive individual PK estimates. It was developed under the direction of Dr. Alfonso Iorio at McMaster University in Hamilton, Ontario, and allows providers to tailor treatment to individual patient characteristics, which leads to better, more cost-effective care. Using population pharmacokinetics means fewer samples need to be drawn from the patient and providers no longer need to perform the calculations. “Being able to submit PK requests directly from ATHN Systems streamlines the data entry process for our ATHN Affiliates, which are the HTCs across the country ATHN partners with,” explains Moses Miles, ATHN’s Chief Operating Officer. “Another benefit of the integration is that the PK estimates generated through WAPPS-Hemo can be used to enrich the ATHNdataset, our safe, secure national data set, which opens up new avenues for research and analysis.” ATHN has indicated that future enhancements to the WAPPS-Hemo / ATHN Systems integration are being planned.
|
